ARGENICA THERAPEUTICS LIMITED (AGN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AGN - ARGENICA THERAPEUTICS LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.61

23 Dec
2024

0.005

OPEN

$0.61

0.83%

HIGH

$0.64

101,933

LOW

$0.61

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 2021202220232024
EPS Basic xxxxxxxxx-5.3
DPS All xxxxxxxxx0.0
Sales/Revenue xxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxx11.3
Net Operating Cash Flow xxxxxxxxx-5.1 M
Net Profit Margin xxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 2021202220232024
Return on Capital Employed xxxxxxxxx-50.70 %
Return on Invested Capital xxxxxxxxx-50.70 %
Return on Assets xxxxxxxxx-42.28 %
Return on Equity xxxxxxxxx-50.70 %
Return on Total Capital xxxxxxxxx-76.50 %
Free Cash Flow ex dividends xxxxxxxxx-

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 2021202220232024
Short-Term Debt xxxxxxxxx0 M
Long Term Debt xxxxxxxxx0 M
Total Debt xxxxxxxxx0 M
Goodwill - Gross xxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxx16 M
Price To Book Value xxxxxxxxx6.94

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 2021202220232024
Capex xxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxx-
Cost of Goods Sold xxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxx8 M
Research & Development xxxxxxxxx6 M
Investments - Total xxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

06/11/2024

1

Buy

$1.15

88.52%

With no safety issues identified, Argenica Therapeutics' Phase 2 stroke trial has been given Data & Safety Monitoring Board approval to continue for the third time. The enrolment rate is stable and is tracking exactly in line with Petra Capital's forecast.

The trial is now 63% recruited and Argenica has reaffirmed its guidance on enrolment completion by end of the Dec Q. Petra continues to expect completion 2-3 months ahead of guidance.

The broker suggests top-line results from the trial remain the key value diver. Buy retained, target rises to $1.15 from $1.14.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -5.90 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.30 cents.

AGN STOCK CHART